Neuren Pharmaceuticals Limited (AU:NEU)
ASX:NEU
Want to see AU:NEU full AI Analyst Report?
NEU Stock Chart & Stats
AU$12.49
-AU$0.38(-3.05%)
At close: 4:00 PM EST
AU$12.49
-AU$0.38(-3.05%)
Day’s Range― - ―
52-Week RangeAU$11.00 - AU$22.99
Previous CloseN/A
Volume294.48K
Average Volume (3M)305.98K
Market Cap
AU$1.74B
Enterprise ValueAU$1.84B
Total Cash (Recent Filing)AU$296.12M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)56.4
Beta2.19
Next Earnings
Aug 25, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.24
Shares Outstanding126,323,975
10 Day Avg. Volume278,541
30 Day Avg. Volume305,983
Financial Highlights & Ratios
PEG Ratio-1.00
Price to Book (P/B)7.05
Price to Sales (P/S)36.92
P/FCF Ratio19.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$23.00Price Target Upside84.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.12
Revenue Forecast (FY)AU$76.02M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA zero-debt capital structure materially reduces financial risk and preserves flexibility to fund R&D, pursue licensing deals or pay milestones without needing immediate external financing. That structural conservatism supports multi-quarter resilience during revenue swings.
High Profitability And MarginsSustained high gross and operating margins indicate the business benefits from low incremental cost of sales (royalties/milestones model), enabling cash generation from revenue spikes and cushioning operating leverage. Durable margins support reinvestment or partner incentives.
Royalty And Licensing Revenue ModelA business model focused on out-licensing transfers commercialization cost and execution risk to partners while creating recurring, scalable royalty streams and milestone inflows. This model lowers fixed costs and capital intensity, improving long-term cash return potential if partners execute.
Bears Say
Revenue Volatility And Recent DeclineLarge year-to-year swings in revenue undermine visibility for R&D pacing, partner negotiations and capital allocation. If royalties and milestones are lumpy, recurring revenue cannot be relied on quarter-to-quarter, increasing the likelihood of financing needs or delayed program timelines.
Inconsistent Cash ConversionIrregular conversion of profits into operating cash reduces predictability of available funds for trials or licensing investments. Persistent intermittency forces management to time deals or seek external capital, raising execution and dilution risk when pipeline needs exceed internal cash.
Very Small Operating Team & Partner DependenceA tiny employee base coupled with reliance on external partners limits in-house development throughput and oversight of commercialization. This structural dependency concentrates execution risk on partner performance, constraining the firm's ability to advance multiple programs simultaneously.
Neuren Pharmaceuticals Limited News
NEU FAQ
What was Neuren Pharmaceuticals Limited’s price range in the past 12 months?
Neuren Pharmaceuticals Limited lowest share price was AU$11.00 and its highest was AU$22.98 in the past 12 months.
What is Neuren Pharmaceuticals Limited’s market cap?
Neuren Pharmaceuticals Limited’s market cap is AU$1.74B.
When is Neuren Pharmaceuticals Limited’s upcoming earnings report date?
Neuren Pharmaceuticals Limited’s upcoming earnings report date is Aug 25, 2026 which is in 82 days.
How were Neuren Pharmaceuticals Limited’s earnings last quarter?
Neuren Pharmaceuticals Limited released its earnings results on Feb 26, 2026. The company reported AU$0.118 earnings per share for the quarter, beating the consensus estimate of AU$0.014 by AU$0.104.
Is Neuren Pharmaceuticals Limited overvalued?
According to Wall Street analysts Neuren Pharmaceuticals Limited’s price is currently Undervalued.
Does Neuren Pharmaceuticals Limited pay dividends?
Neuren Pharmaceuticals Limited does not currently pay dividends.
What is Neuren Pharmaceuticals Limited’s EPS estimate?
Neuren Pharmaceuticals Limited’s EPS estimate is 0.05.
How many shares outstanding does Neuren Pharmaceuticals Limited have?
Neuren Pharmaceuticals Limited has 126,323,975 shares outstanding.
What happened to Neuren Pharmaceuticals Limited’s price movement after its last earnings report?
Neuren Pharmaceuticals Limited reported an EPS of AU$0.118 in its last earnings report, beating expectations of AU$0.014. Following the earnings report the stock price went down -2.902%.
Which hedge fund is a major shareholder of Neuren Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in AU:NEU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neuren Pharmaceuticals Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$23.00 (84.15% Upside)
AU$23.00 (84.15% Upside)
Blogger Sentiment
Bullish
AU:NEU Sentiment 99%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$151.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
63.76%
12-Months-Change
Fundamentals
Return on Equity
9.20%
Trailing 12-Months
Asset Growth
-9.87%
Trailing 12-Months
Company Description
Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.
NEU Stock 12 Month Forecast
Average Price Target
AU$23.00
▲(84.15% Upside)
Technical Analysis
Actinogen Medical
―
Opthea
―
Zelira Therapeutics
―
PYC Therapeutics Limited
―
Neuroscientific Biopharmaceuticals Ltd.
―
Options Prices
Currently, No data available
---